Abstract
BACKGROUND:Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy.OBJECTIVE:The purpose of this study was to assess RTX as a maintenance therapy in RNMO.METHODS:Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months.RESULTS:After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening.CONCLUSIONS:RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.